On October 8, INNOVENT BIO fell 3.18% in regular trading, trading at HK$94.45, with Turnover of HK$414 million.

News catalysts include the company's September monthly share movement statement showing issued shares increased to 1.7469 billion with no buybacks during the period, while the broader biotech sector remained weak with concurrent declines in key peers.

INNOVENT BIO is a biopharmaceutical company focused on R&D, production and sales of innovative drugs for oncology, cardiovascular and metabolic diseases, autoimmune and ophthalmic diseases. Drug formats include monoclonal antibodies, bispecific antibodies, immune cytokines, ADCs, cell therapy and small molecule drugs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)